Please ensure Javascript is enabled for purposes of website accessibility

Here's Why BeiGene, Ltd. Jumped 38.9% in January

By Cory Renauer - Feb 5, 2018 at 4:03PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Celgene Corporation's partner in China is getting busy with tislelizumab.

What happened

Shares of BeiGene Ltd. (BGNE -9.01%), a clinical-stage biotech developing new cancer therapies, climbed 38.9% in January, according to data from S&P Global Market Intelligence. The initiation of another pivotal trial with a Celgene Corporation (CELG)-partnered new therapy candidate, following a successful offering, made last month one to remember.

So what 

BeiGene's deal with Celgene is heating up. The China-based company began a pivotal liver cancer trial with tislelizumab to begin in January, then started the anti-PD-1 antibody's third global pivotal study with esophageal cancer patients to close out the month. In China, investigators are also running pivotal studies with Hodgkin lymphoma and bladder cancer patients.

Person drawing an upward sloping chart with their fingers.

Image source: Getty Images.

After receiving $413 million from Celgene in the last half of 2017, BeiGene wasn't exactly strapped for cash. Following a monstrous $800 million follow-on offering of the company's U.S.-traded shares in the middle of January, it should have more than enough to keep operations humming along for years to come. Although the size of the offering was impressive, pricing it at $101.00 signaled confidence that also drove the stock higher.

Now what

Tislelizumab is just one of four potential new cancer therapies BeiGene has in clinical-stage development at the moment. Although the company has run a tight ship, racking up just $215 million in operating expenses in the first nine months of 2017, the quarters ahead could get a lot more expensive.

Luckily for BeiGene, cash raised from the U.S. offering, plus rights to sell Celgene's products in China, will go a long way to fund development of the company's burgeoning pipeline. Tislelizumab is just one of four candidates Beigene is testing in clinical-stage trials at the moment.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

BeiGene Stock Quote
$122.99 (-9.01%) $-12.18
Celgene Corporation Stock Quote
Celgene Corporation

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/25/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.